Kirkland Represents Arya Sciences Acquisition Corp. on Business Combination with Immatics Biotechnologies

Kirkland & Ellis is advising Arya Sciences Acquisition Corp. (NASDAQ: ARYA), a special purpose acquisition company sponsored by Perceptive Advisors, on its business combination with Immatics Biotechnologies GmbH, a clinical-stage biopharmaceutical company active in the discovery and development of T cell redirecting cancer immunotherapies. Upon the successful completion of the business combination, the combined company is expected to be listed on NASDAQ under the ticker symbol “IMTX” and have an initial market capitalization of approximately $634 million. Completion of the transaction is expected in the second quarter of 2020. 

Read the company press release

The Kirkland team was led in New York by transactional partners Ryan Brissette and Jonathan Davis and associate Matthew Benedetto; capital markets partners Christian Nagler and Peter Seligson; tax partner partner Sara Zablotney; and executive compensation partner Michael Krasnovsky; and in Munich by corporate partner Volkmar Bruckner and tax partner Oded Shein.